ReviewMedical oncology (Northwood, London, England)2019
Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.
Review in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma.Cell reports. Medicine · 2026Article
- POU2F3-positive small cell neuroendocrine carcinoma of the urinary tract: a clinicopathological analysis of five cases.Frontiers in oncology · 2026Article
- Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.Biomolecules & biomedicine · 2025Review
- Small cell carcinoma with rhabdomyosarcomatous differentiation of the urinary bladder: an integrated clinicopathological and molecular characterization of five cases.Virchows Archiv : an international journal of pathology · 2025Article
- Clinicopathological features and prognosis of small cell carcinoma of the urinary bladder.Asian journal of urology · 2025Article
- Deciphering riddles in molecular subtyping of bladder cancer.Asian journal of urology · 2025Review
- Treatment and survival of non-metastatic small cell carcinoma of the bladder from multiple centers in China.Scientific reports · 2024Article
- Small cell neuroendocrine carcinoma and poorly differentiated rhabdomyosarcomas of the urinary bladder in adults-A comparative analysis in favor of a common histogenesis.Virchows Archiv : an international journal of pathology · 2024Article
- Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.Current oncology (Toronto, Ont.) · 2024Article
- Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment.Cancer research and treatment · 2024Article
- Primary Small Cell Carcinoma of the Bladder.Cureus · 2021Article
- Classification of bladder cancer cell lines according to regulon activity.Turkish journal of biology = Turk biyoloji dergisi · 2021Article
- Small cell carcinoma of the bladder with coexisting prostate adenocarcinoma: two cases report and literature review.BMC urology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Small cell carcinoma of the bladder (SCCB) is a rare disease associated with high invasiveness and mortality. Histologically, SCCB is difficult to distinguish from small cell lung cancer (SCLC); however, it shares more similar molecular alterations with urothelial carcinoma (UC). As a result, now, the widely accepted theory about the cells of origin is that SCCB and UC probably have a common clone origin. Even the former probably comes from a preexisting UC. At present, given its rarity, early diagnoses, treatments, and follow-ups are not well established, which are vital to patients with SCCB. Inspirationally, in recent years, with the development of molecular diagnostic methods, molecular alterations of SCCB have been understood partially, which are propitious to excavate new potential therapeutic strategies and establish sound follow-ups. Therefore, the future will be light for patients with SCCB.
Indexed as
Identifiers
31664527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.